JP7834746B2 - ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体 - Google Patents

ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体

Info

Publication number
JP7834746B2
JP7834746B2 JP2023526360A JP2023526360A JP7834746B2 JP 7834746 B2 JP7834746 B2 JP 7834746B2 JP 2023526360 A JP2023526360 A JP 2023526360A JP 2023526360 A JP2023526360 A JP 2023526360A JP 7834746 B2 JP7834746 B2 JP 7834746B2
Authority
JP
Japan
Prior art keywords
pyran
triazole
hydroxymethyl
carboxamide
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023526360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547241A (ja
JP2023547241A5 (enExample
Inventor
ボリ マーティン
ガットフィールド ジョン
グリソストミ コリンナ
レメン ルボス
ザーガー クリストフ
ツムブルン コルネリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2023547241A publication Critical patent/JP2023547241A/ja
Publication of JP2023547241A5 publication Critical patent/JP2023547241A5/ja
Application granted granted Critical
Publication of JP7834746B2 publication Critical patent/JP7834746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
JP2023526360A 2020-11-02 2021-11-01 ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体 Active JP7834746B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2020080681 2020-11-02
EPPCT/EP2020/080681 2020-11-02
EPPCT/EP2021/053133 2021-02-10
EP2021053133 2021-02-10
PCT/EP2021/080276 WO2022090544A1 (en) 2020-11-02 2021-11-01 Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives

Publications (3)

Publication Number Publication Date
JP2023547241A JP2023547241A (ja) 2023-11-09
JP2023547241A5 JP2023547241A5 (enExample) 2024-11-13
JP7834746B2 true JP7834746B2 (ja) 2026-03-24

Family

ID=78414042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526360A Active JP7834746B2 (ja) 2020-11-02 2021-11-01 ガレクチン－３を阻害する２－ヒドロキシシクロアルカン－１－カルバモイル誘導体

Country Status (10)

Country Link
US (1) US12291520B2 (enExample)
EP (1) EP4237419A1 (enExample)
JP (1) JP7834746B2 (enExample)
KR (1) KR20230104190A (enExample)
AU (1) AU2021370994A1 (enExample)
CA (1) CA3197095A1 (enExample)
IL (1) IL302421A (enExample)
MX (1) MX2023005039A (enExample)
TW (1) TWI910255B (enExample)
WO (1) WO2022090544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン－カルバモイル誘導体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2020139960A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc Galectin-3 inhibiting c-glycosides
WO2020198266A1 (en) 2019-03-26 2020-10-01 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (enExample) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
CN109563119A (zh) 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2020139960A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc Galectin-3 inhibiting c-glycosides
WO2020198266A1 (en) 2019-03-26 2020-10-01 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3

Also Published As

Publication number Publication date
CA3197095A1 (en) 2022-05-05
TW202233609A (zh) 2022-09-01
MX2023005039A (es) 2023-05-16
JP2023547241A (ja) 2023-11-09
IL302421A (en) 2023-06-01
KR20230104190A (ko) 2023-07-07
AU2021370994A1 (en) 2023-06-29
TWI910255B (zh) 2026-01-01
US20230348442A1 (en) 2023-11-02
WO2022090544A1 (en) 2022-05-05
EP4237419A1 (en) 2023-09-06
US12291520B2 (en) 2025-05-06

Similar Documents

Publication Publication Date Title
KR102832308B1 (ko) 2-히드록시시클로알칸-1-카르바모일 유도체
JP7844491B2 (ja) ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
US12291520B2 (en) Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
JP7757399B2 (ja) アルファ－ｄ－ガラクトピラノシドのスピロ誘導体
CN116745282A (zh) 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3
EA050798B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3
HK40101885B (en) Hydroxyheterocycloalkane-carbamoyl derivatives
HK40101885A (en) Hydroxyheterocycloalkane-carbamoyl derivatives
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные
HK40071801A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
HK40071801B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20251114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260311

R150 Certificate of patent or registration of utility model

Ref document number: 7834746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150